NDAORALTABLETPriority Review
Approved
Jan 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
13
Mechanism of Action
Estrogen Receptor Antagonists
Pharmacologic Class:
Estrogen Receptor Antagonist
Clinical Trials (5)
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
Started Mar 2026
65 enrolled
Metastatic Breast CancerHER2 Low Breast CarcinomaHER2-negative Breast Cancer+2 more
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Started Feb 2026
30 enrolled
Uterine SarcomaUterine LeiomyosarcomaEndometrial Stromal Sarcoma+6 more
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Started Jan 2026
297 enrolled
Estrogen-receptor-positive Breast CancerMetastatic Breast CancerBreast Cancer+6 more
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
Started Dec 2024
176 enrolled
Hormone Receptor Positive HER-2 Negative Breast CancerAdvanced or Metastatic Breast CancerBRCA1 Mutation+1 more
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Started Dec 2024
240 enrolled
Advanced Breast CancerER-positive Breast CancerHER2-negative Breast Cancer+1 more
Loss of Exclusivity
LOE Date
Jan 5, 2038
144 months away
Patent Expiry
Jan 5, 2038
Exclusivity Expiry
Jan 27, 2028